About: Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors
Creator	Ng, Van Goor, Harry Friedrich, Alex Anker, Stefan Cleland, John Filippatos, Gerasimos Metra, Marco Ponikowski, Piotr Sama, Iziah Van Veldhuisen, Dirk Voors, Adriaan Samani, Nilesh Leong, L Dickstein, Kenneth Lang, Chim Ravera, Alice Rienstra, Michiel Santema, Bernadet Ter Maaten, Jozine
source	Medline; PMC
abstract	AIMS: The current pandemic coronavirus SARS-CoV-2 infects a wide age group but predominantly elderly individuals, especially men and those with cardiovascular disease. Recent reports suggest an association with use of renin–angiotensin–aldosterone system (RAAS) inhibitors. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for coronaviruses. Higher ACE2 concentrations might lead to increased vulnerability to SARS-CoV-2 in patients on RAAS inhibitors. METHODS AND RESULTS: We measured ACE2 concentrations in 1485 men and 537 women with heart failure (index cohort). Results were validated in 1123 men and 575 women (validation cohort). The median age was 69 years for men and 75 years for women. The strongest predictor of elevated concentrations of ACE2 in both cohorts was male sex (estimate = 0.26, P < 0.001; and 0.19, P < 0.001, respectively). In the index cohort, use of ACE inhibitors, angiotensin receptor blockers (ARBs), or mineralocorticoid receptor antagonists (MRAs) was not an independent predictor of plasma ACE2. In the validation cohort, ACE inhibitor (estimate = –0.17, P = 0.002) and ARB use (estimate = –0.15, P = 0.03) were independent predictors of lower plasma ACE2, while use of an MRA (estimate = 0.11, P = 0.04) was an independent predictor of higher plasma ACE2 concentrations. CONCLUSION: In two independent cohorts of patients with heart failure, plasma concentrations of ACE2 were higher in men than in women, but use of neither an ACE inhibitor nor an ARB was associated with higher plasma ACE2 concentrations. These data might explain the higher incidence and fatality rate of COVID-19 in men, but do not support previous reports suggesting that ACE inhibitors or ARBs increase the vulnerability for COVID-19 through increased plasma ACE2 concentrations.
has issue date	2020-05-14(xsd:dateTime)
bibo:doi	10.1093/eurheartj/ehaa373
bibo:pmid	32388565
has license	no-cc
sha1sum (hex)	b8f860392e86925825f3af162c9299c3bd9c6dfe
schema:url	https://doi.org/10.1093/eurheartj/ehaa373
resource representing a document's title	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors
has PubMed Central identifier	PMC7239195
has PubMed identifier	32388565
schema:publication	Eur Heart J
resource representing a document's body	covid:b8f860392e86925825f3af162c9299c3bd9c6dfe#body_text
is schema:about of	named entity 'group' named entity 'RAAS' named entity 'plasma' named entity 'BUT' named entity 'CORONAVIRUSES' named entity 'PANDEMIC' named entity 'CURRENT' named entity 'ASSOCIATION' named entity 'RENIN' named entity 'PLASMA CONCENTRATIONS' named entity 'HEART FAILURE' named entity 'ACE2' named entity 'Higher' named entity 'renin-angiotensin-aldosterone system' named entity 'inhibitors' named entity 'Recent' named entity 'patients' named entity 'coronaviruses' named entity 'ACE2' named entity 'ACE2' named entity 'cardiovascular disease' named entity 'heart failure' named entity 'angiotensin-converting enzyme 2' named entity 'renal disease' named entity 'Medtronic' named entity 'ACE2' named entity 'heart failure' named entity 'ACE2' named entity 'ACE2' named entity 'Abbott Vascular' named entity 'plasma' named entity 'heart failure' named entity 'ACE2' named entity 'SARS-CoV' named entity 'infection' named entity 'ACE2' named entity 'ACE2' named entity 'ARBs' named entity 'plasma' named entity 'alveolar epithelial cells' named entity 'ACE2' named entity 'Novartis' named entity 'protein' named entity 'heart failure' named entity 'fatality rate' named entity 'ACE2' named entity 'ARB' named entity 'plasma' named entity 'analysis of variance' named entity 'Abbott vascular' named entity 'ACE inhibitor' named entity 'COVID-19 disease' named entity 'ACE2' named entity 'ACE2' named entity 'statistically significant' named entity 'heart failure' named entity 'oligonucleotides' named entity 'lungs' named entity 'ARBs' named entity 'non-normally distributed' named entity 'angiotensin receptor blockers' named entity 'ACE inhibitor' named entity 'MRAs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software